Neurogene Future Growth
Future criteria checks 0/6
Neurogene's earnings are forecast to decline at 33.6% per annum while its annual revenue is expected to grow at 66.5% per year. EPS is expected to decline by 85.1% per annum.
Key information
-33.6%
Earnings growth rate
-85.1%
EPS growth rate
| Biotechs earnings growth | 24.4% |
| Revenue growth rate | 66.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -86 | -83 | -81 | 4 |
| 12/31/2025 | N/A | -75 | -76 | -71 | 5 |
| 12/31/2024 | N/A | -66 | -69 | -59 | 5 |
| 12/31/2023 | N/A | 14 | -52 | -51 | N/A |
| 9/30/2023 | N/A | -51 | -45 | -45 | N/A |
| 6/30/2023 | N/A | -49 | -44 | -44 | N/A |
| 3/31/2023 | N/A | -52 | -50 | -48 | N/A |
| 12/31/2022 | N/A | -55 | -55 | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NGNE's earnings are forecast to decline over the next 3 years (-33.6% per year).
Earnings vs Market: NGNE's earnings are forecast to decline over the next 3 years (-33.6% per year).
High Growth Earnings: NGNE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: NGNE is forecast to have no revenue next year.
High Growth Revenue: NGNE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NGNE's Return on Equity is forecast to be high in 3 years time